硬化性黏液水肿，一种治疗难题。

Scleromyxedema, a therapeutic dilemma.

作者信息

Salas-Alanis Julio Cesar, Martinez-Jaramillo Brayant, Gomez-Flores Minerva, Ocampo-Candiani Jorge

机构信息

Basic Science, School of Medicine, Universidad de Monterrey, Nuevo León, Mexico, USA.

Department of Dermatology, University Hospital "Dr. Jose E. González", Universidad Autonoma de Nuevo Leon, Nuevo León, Mexico, USA.

出版信息

Indian J Dermatol. 2015 Mar-Apr;60(2):215. doi: 10.4103/0019-5154.152600.

DOI:10.4103/0019-5154.152600

PMID:25814746

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4372950/

Abstract

Scleromyxedema is characterized by indurated erythematous papules disseminated on the face, chest and limbs. About twenty cases treated with thalidomide, stem cells, melphalan and immunoglobulin with varying results have been described. We present the case of a 28-year-old male patient diagnosed with scleromyxedema not associated with monoclonal gammopathy, multi-treated with anti-leprosy drugs, UVA1, and thalidomide for 4 years with no improvement.

摘要

硬化性黏液水肿的特征是在面部、胸部和四肢出现硬结性红斑丘疹。已有约20例使用沙利度胺、干细胞、美法仑和免疫球蛋白治疗的病例报道，疗效各异。我们报告了一例28岁男性患者，诊断为不伴有单克隆丙种球蛋白病的硬化性黏液水肿，曾联合使用抗麻风药、UVA1和沙利度胺治疗4年，但病情无改善。